Orally delivered targeted nanotherapeutics for the treatment of colorectal cancer

References

• Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–114.
   PubMed Web of Science ®Google Scholar
• Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–197.
   PubMedGoogle Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Parisa A, Ramin R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol. 2016;22(25):5678–5693.
   PubMed Web of Science ®Google Scholar
• Albasri A, Yosef H, Hussainy AS, et al. Histopathological features of colorectal cancer in Al-madinah region of saudi arabia: 8 years experience. Asian Pac J Cancer Prev. 2014;15(7):3133–3137.
   PubMedGoogle Scholar
• Jawed I, Wilkerson J, Duffy AG, et al. Twenty years of chemotherapy for colorectal cancer (CRC): progress made, insights gleaned. Jpn J Clin Oncol. 2012;30(4):596.
   Google Scholar
• Pinto JF. Site-SPECIFIC drug delivery systems within the gastro-intestinal tract: from the mouth to the colon. Int J Pharm. 2010;395(1–2):44–52.
   PubMed Web of Science ®Google Scholar
• Simonian HP, Vo L, Doma S, et al. Regional postprandial differences in pH within the stomach and gastroesophageal junction. Dig Dis Sci. 2005;50(12):2276–2285.
   PubMed Web of Science ®Google Scholar
• Ankita D, Ashish B, Raj KN. Nanoparticles as carriers for drug delivery in cancer. Artif Cell Nanomed B. 2018;46(2):295–305.
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Canc. 2015;14(1):1–10.
   PubMed Web of Science ®Google Scholar
• Van der JK, Xu HC, Li YJ, et al. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834–3848.
   PubMed Web of Science ®Google Scholar
• Tonini G, Calvieri A, Vincenzi B, et al. First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther. 2009;2:73–82.
   PubMed Web of Science ®Google Scholar
• Pazdur R, Hoff PM, Medgyesy D, et al. The oral fluorouracil prodrugs. Oncology. 1998;12(10):48–51.
   PubMed Web of Science ®Google Scholar
• Kiyonari S, Iimori M, Matsuoka K, et al. The 1,2-diaminocyclohexane carrier ligand in oxaliplatin Induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis. Mol Cancer Ther. 2015;14(10):2332–2342.
   PubMed Web of Science ®Google Scholar
• Gerd P, Stenius U, Seidel A, et al. DNA adducts derived from tumorigenic benzo [a] pyrene and dibenzo [a,l] pyrene and activation of Mdm2 and p53. Cancer Res. 2006;66:88.
   Web of Science ®Google Scholar
• Xiao B, Si XY, Han MK, et al. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B. 2015;3(39):10.1039.C5TB01245G.
   Web of Science ®Google Scholar
• Malingré MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drug. 2001;19(2):155–162.
   PubMed Web of Science ®Google Scholar
• Ding C, Li L, Yang T, et al. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer. 2016;16(1):791–803.
   PubMedGoogle Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.
   PubMed Web of Science ®Google Scholar
• McQuade RM, Stojanovska V, Bornstein JC, et al. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–1557.
   PubMed Web of Science ®Google Scholar
• Ravindranathan P, Pasham D, Balaji U, et al. A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer. Sci Rep. 2018;8:13869.
   PubMed Web of Science ®Google Scholar
• Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008;57(11):1509–1517.
   PubMed Web of Science ®Google Scholar
• Lao CD, Ruffin M, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6(1):10.
   PubMedGoogle Scholar
• Clamp AR, Schoffski P, Valle JW, et al. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61(4):579–585.
   PubMed Web of Science ®Google Scholar
• Dragovich T, Mendelson D, Kurtin S, et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58(6):759–764.
   PubMed Web of Science ®Google Scholar
• Batist G, Gelmon KA, Chi KN, et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):692–700.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC- a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12(10):607–619.
   PubMed Web of Science ®Google Scholar
• Shen MY, Liu TI, Yu TW, et al. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer. Biomaterials. 2019;197:86–100.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2012;64:61–71.
   Web of Science ®Google Scholar
• Xiao B, Laroui H, Ayyadurai S, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials. 2013;34:7471–7482.
   PubMed Web of Science ®Google Scholar
• Ayyadurai S, Charania MA, Xiao B, et al. PepT1 expressed in immune cells has an important role in promoting the immune response during experimentally induced colitis. Lab Invest. 2013;93:888–899.
   PubMed Web of Science ®Google Scholar
• Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv. 2004;11(2):129–148.
   PubMed Web of Science ®Google Scholar
• Liu LS, Fishman ML, Kost J, et al. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003;24(19):3333–3343.
   PubMed Web of Science ®Google Scholar
• Subudhi MB, Jain A, Jain A, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil. Materials. 2015;8(3):832–849.
   PubMed Web of Science ®Google Scholar
• Bonnaud M, Weiss J, McClements DJ. Interaction of a food-grade cationic surfactant (lauric arginate) with food-grade biopolymers (pectin, carrageenan, xanthan, alginate, dextran, and chitosan). J Agr Food Chem. 2010;58(17):9770–9777.
   PubMed Web of Science ®Google Scholar
• Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the plasma exposure of (−)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci. 2011;44(3):422–426.
   PubMed Web of Science ®Google Scholar
• Huang H-C, Barua S, Sharma G, et al. Inorganic nanoparticles for cancer imaging and therapy. J Control Release. 2011;155(3):344–357.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhu Y, Wang F, et al. Galactosylated chitosan-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Roy Soc Open Sci. 2018;5(12):181027–181039.
   PubMed Web of Science ®Google Scholar
• Satapathy SR, Mohapatra P, Preet R, et al. Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. Nanomedicine. 2013;8(8):1307–1322.
   PubMed Web of Science ®Google Scholar
• Mu J, Zhuang X, Wang Q, et al. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol Nutr Food Res. 2014;58(7):1561–1573.
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng Y, Zhao M. Exosome-based cancer therapy: implication for targeting cancer stem cells. Front Pharmacol. 2017;7:533.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xiao B, Wang H, et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther. 2016;24(10):1783–1796.
   PubMed Web of Science ®Google Scholar
• Xiao B, Yang Y, Viennois E, et al. Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticles. J Mater Chem B. 2014;2(11):1499–1508.
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Lugering A, Yan Y, et al. Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab InvesT. 2005;85(7):932–941.
   PubMed Web of Science ®Google Scholar
• Xiao B, Viennois E, Chen Q, et al. Silencing of intestinal glycoprotein CD98 by orally targeted nanoparticles enhances chemosensitization of colon cancer. ACS Nano. 2018;12(6): 5253–5265. .
   PubMed Web of Science ®Google Scholar
• Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2017;9:790–810.
   PubMed Web of Science ®Google Scholar
• Harada T, Arii S, Mise M, et al. Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol. 1998;28:231–239.
   PubMed Web of Science ®Google Scholar
• Remacle A, Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci. 2003;116(19):3905–3916.
   PubMed Web of Science ®Google Scholar
• Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer. 2004;108(2):301–306.
   PubMed Web of Science ®Google Scholar
• Bendardaf R, Algars A, Elzagheid A, et al. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep. 2006;16(4):741–746.
   PubMed Web of Science ®Google Scholar
• Xiao B, Han MK, Viennois E, et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale. 2015;7(42):17745–17755.
   PubMed Web of Science ®Google Scholar
• Akhter DT, Simpson JD, Fletcher NL, et al. Oral delivery of multicompartment nanomedicines for colorectal cancer therapeutics: combining loco-regional delivery with cell-target specificity. Adv Ther. 2019;3:1900171.
   Google Scholar
• Xu JQ, Zhang YL, Xu JC, et al. Reversing tumor stemness via orally targeted nanoparticles achieves efficient colon cancer treatment. Biomaterials. 2019;216:119247–119257.
   PubMed Web of Science ®Google Scholar
• Zu MH, Ma LJ, Zhang XQ, et al. Chondroitin sulfate-functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy. Colloid Surf B. 2019;177:399–406.
   PubMed Web of Science ®Google Scholar
• Ababneh N, Alshaer W, Allozi O, et al. In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker. Nucleic Acid Ther. 2013;23(6):401–407.
   PubMed Web of Science ®Google Scholar
• Xie X, Li F, Zhang H, et al. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur J Pharm Sci. 2016;83:28–35.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539(7630):479.
   PubMed Web of Science ®Google Scholar
• Song W, Shen L, Wang Y, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018;9(1): 2237–2247. .
   PubMed Web of Science ®Google Scholar
• Shen L, Shi Q, Wang W. Double agents: genes with both oncogenic and tumor-suppressor functions. Oncogenesis. 2018;7(3):25.
   PubMedGoogle Scholar
• Martinez-Lage M, Puig-Serra P, Menendez P, et al. CRISPR/Cas9 for cancer therapy: hopes and challenges. Biomedicines. 2018;6(4):105–117.
   Web of Science ®Google Scholar
• Carboni V, Maaliki C, Alyami M, et al. Synthetic vehicles for encapsulation and delivery of CRISPR/Cas9 gene editing machinery. Adv Ther. 2019;2(4):1800085–1800093.
   Google Scholar
• Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17:156–166.
   PubMed Web of Science ®Google Scholar
• Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat Biomed Eng. 2019;3(9):717–728.
   PubMed Web of Science ®Google Scholar
• Bai X, Ming K, Wu XJ, et al. Multi-responsive biomimetic nano-complex platform for enhanced gene delivery. J Mater Chem B. 2018;6:5910–5921.
   PubMed Web of Science ®Google Scholar
• Keyashian K. Does endoscopic assessment of mucosal healing affect IBD management? Dig Dis Sci. 2014;59(10):2351–2353.
   PubMed Web of Science ®Google Scholar